NZOZ SALUSMED

The cardiology department is studying uncontrolled hypertension and resistant hypertension, with the goal of evaluating a new therapy that could lower systolic blood pressure when existing drugs are insufficient.

• Assessment of systolic blood pressure reduction
• Safety and tolerability profiling
• Comparison with placebo treatment
• Impact on patients using multiple antihypertensive agents

The trials test the novel agent baxdrostat over a 12‑week period, seeking evidence that it can provide an effective option for individuals whose blood pressure remains above target despite standard therapy.

The clinic is conducting research on iron‑deficient recent myocardial infarction patients to determine whether intravenous ferric carboxymaltose can reduce mortality and improve cardiovascular outcomes.

• Evaluation of death and heart‑failure event risk
• Monitoring of NT‑proBNP concentrations
• Assessment of health‑related quality of life (EQ‑5D)
• Long‑term follow‑up up to 36 months

Using a hierarchical win‑ratio approach, the study aims to demonstrate clinical benefits of iron repletion therapy in patients recovering from a heart attack while addressing iron deficiency.